Dr. Stephen Forman Joins Lixte Biotechnology's Board of Directors
June 07 2016 - 9:35AM
Marketwired
Dr. Stephen Forman Joins Lixte Biotechnology's Board of
Directors
EAST SETAUKET, NY-(Marketwired - Jun 7, 2016) - Lixte
Biotechnology Holdings, Inc. (OTCQB: LIXT) announced today the
appointment of Stephen J. Forman, M.D., to the Board of Directors
of Lixte. Dr. Forman is Director of the T cell Therapeutics
Research Laboratory, Director of the Hematologic Malignancies and
Stem Cell Transplantation Institute, and holds the Francis and
Kathleen McNamara Distinguished Chair in Hematology and
Hematopoietic Cell Transplantation at the City of Hope National
Medical Center in Duarte, California. He is co-editor of Thomas'
Hematopoietic Cell Transplantation, a definitive textbook for
clinicians, scientists and health care professionals.
John S. Kovach, M.D., President and CEO of Lixte, commented, "We
are delighted to welcome Dr. Stephen J. Forman to Lixte's Board.
Dr. Forman is an internationally recognized leader in preclinical
and clinical cancer research. In the past few years, he has
expanded his laboratory research to include immunological
approaches to cancer. Pharmacological enhancement of patients'
immune responses to their cancers is of special interest to Lixte
as the enzyme target of its lead clinical compound, LB-100, has
been reported recently to be critical to immune function. Dr.
Forman's judgment and expertise in cancer drug development will
prove an invaluable addition to Lixte as we work towards bringing
improved treatments of human cancers and other life-threatening
diseases to clinical practice."
About Lixte Biotechnology Holdings, Inc. Lixte is a drug
discovery company that uses biomarker technology to identify enzyme
targets associated with serious common diseases and then design
novel compounds to attack those targets. Lixte's product pipeline
encompasses two major categories of compounds at various stages of
pre-clinical and clinical development that the Company believes
have broad therapeutic potential not only for cancer but also for
other debilitating and life-threatening diseases. Lixte's unique
phosphatase inhibitor, LB-100, is completing a Phase I clinical
trial at two NCI designated Comprehensive Cancer Centers and three
US Oncology Research sites (see ClinicalTrials.gov: Identifier
NCTO1837667).
Forward-Looking Statements This announcement contains certain
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, and Section 21E of the Securities Exchange
Act of 1934. For example, statements regarding the Company's
financial position, business strategy and other plans and
objectives for future operations, and assumptions and predictions
about future product demand, supply, manufacturing, costs,
marketing and pricing factors are all forward-looking statements.
These statements are generally accompanied by words such as
"intend," anticipate," "believe," "estimate," "potential(ly),"
"continue," "forecast," "predict," "plan," "may," "will," "could,"
"would," "should," "expect" or the negative of such terms or other
comparable terminology. The Company believes that the assumptions
and expectations reflected in such forward-looking statements are
reasonable, based on information available to it on the date
hereof, but the Company cannot provide assurances that these
assumptions and expectations will prove to have been correct or
that the Company will take any action that the Company may
presently be planning. However, these forward-looking statements
are inherently subject to known and unknown risks and
uncertainties. Actual results or experience may differ materially
from those expected or anticipated in the forward-looking
statements. Factors that could cause or contribute to such
differences include, but are not limited to, regulatory policies,
available cash, research results, competition from other similar
businesses, and market and general economic factors. This
discussion should be read in conjunction with the Company's filings
with the United States Securities and Exchange Commission at
http://www.sec.gov/edgar.shtml.
Additional information on the Company is available at
www.lixte.com.
Contact Information
Corporate Contact: Eric J. Forman, Esq. 646-894-3135
eforman@lixte.com